{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:26:45Z","timestamp":1793395605448,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13318-025-00969-w","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:56:25Z","timestamp":1762325785000},"page":"47-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tacrolimus Pharmacokinetics in Pediatric Liver Transplant Recipients During the First Month After Transplantation"],"prefix":"10.1007","volume":"51","author":[{"given":"Femke A.","family":"Elzinga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea R.","family":"Hernandez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert P. J.","family":"van der Doef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos G. W.","family":"Kosterink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A. H.","family":"Loeffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Scheenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno R.","family":"Bourgonje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-1201","authenticated-orcid":false,"given":"Paola","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"4","key":"969_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.cld.2018.06.004","volume":"22","author":"YH Pham","year":"2018","unstructured":"Pham YH, Miloh T. Liver transplantation in children. Clin Liver Dis. 2018;22(4):807\u201321.","journal-title":"Clin Liver Dis"},{"key":"969_CR2","doi-asserted-by":"crossref","unstructured":"Webb NJA, Baumann U, Camino M, Frauca E, Undre N. Pharmacokinetics of tacrolimus granules in pediatric de novo liver, kidney, and heart transplantation: the OPTION study. Pediatr Transplant. 2019;23(1).","DOI":"10.1111\/petr.13328"},{"issue":"11","key":"969_CR3","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.4254\/wjh.v7.i11.1509","volume":"7","author":"C Hackl","year":"2015","unstructured":"Hackl C. Current developments in pediatric liver transplantation. World J Hepatol. 2015;7(11):1509.","journal-title":"World J Hepatol"},{"key":"969_CR4","doi-asserted-by":"crossref","unstructured":"de Ville de Goyet J, Baumann U, Karam V, Adam R, Nadalin S, Heaton N, et al. European Liver Transplant Registry: donor and transplant surgery aspects of 16,641 liver transplantations in children. Hepatology. 2022;75(3):634\u201345.","DOI":"10.1002\/hep.32223"},{"issue":"4","key":"969_CR5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1517\/14656566.9.4.635","volume":"9","author":"LJ Bowman","year":"2008","unstructured":"Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother. 2008;9(4):635\u201343.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"969_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of Tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"969_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","volume":"48","author":"T Vanhove","year":"2016","unstructured":"Vanhove T, Annaert P, Kuypers DRJ. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev. 2016;48(1):88\u2013112.","journal-title":"Drug Metab Rev"},{"issue":"3","key":"969_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jcph.1325","volume":"59","author":"O Campagne","year":"2019","unstructured":"Campagne O, Mager DE, Tornatore KM. Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities? J Clin Pharmacol. 2019;59(3):309\u201325.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"969_CR9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s40262-016-0396-1","volume":"55","author":"E Brooks","year":"2016","unstructured":"Brooks E, Tett SE, Isbel NM, Staatz CE. Population pharmacokinetic modelling and Bayesian estimation of tacrolimus exposure: is this clinically useful for dosage prediction yet? Clin Pharmacokinet. 2016;55(11):1295\u2013335.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"969_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623\u201353.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"969_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0b013e31823415cc","volume":"33","author":"JE Wallin","year":"2011","unstructured":"Wallin JE, Bergstrand M, Wilczek HE, Nydert PS, Karlsson MO, Staatz CE. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. Ther Drug Monit. 2011;33(6):663\u201372.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"969_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1046\/j.1397-3142.2000.00000.x","volume":"5","author":"GD MacFarlane","year":"2001","unstructured":"MacFarlane GD, Venkataramanan R, McDiarmid SV, Pirsch JD, Scheller DG, Ersfeld DL, et al. Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients. Pediatr Transplant. 2001;5(2):119\u201324.","journal-title":"Pediatr Transplant"},{"issue":"2","key":"969_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/FTD.0b013e318198d092","volume":"31","author":"P Wallemacq","year":"2009","unstructured":"Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, et al. Opportunities to optimize Tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31(2):139\u201352.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"969_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/aor.13551","volume":"44","author":"Y Bentata","year":"2020","unstructured":"Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs. 2020;44(2):140\u201352.","journal-title":"Artif Organs"},{"issue":"3","key":"969_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/ajt.15665","volume":"20","author":"Q Ling","year":"2020","unstructured":"Ling Q, Huang H, Han Y, Zhang C, Zhang X, Chen K, et al. The tacrolimus-induced glucose homeostasis imbalance in terms of the liver: from bench to bedside. Am J Transplant. 2020;20(3):701\u201313.","journal-title":"Am J Transplant"},{"issue":"8","key":"969_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.mpaic.2018.05.005","volume":"19","author":"TG Hansen","year":"2018","unstructured":"Hansen TG. Developmental paediatric anaesthetic pharmacology. Anaesth Intensive Care Med. 2018;19(8):437\u201343.","journal-title":"Anaesth Intensive Care Med"},{"issue":"1","key":"969_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","volume":"46","author":"CE Staatz","year":"2007","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13\u201358.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"969_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","volume":"29","author":"N Shuker","year":"2015","unstructured":"Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev. 2015;29(2):78\u201384.","journal-title":"Transplant Rev"},{"key":"969_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2023.464086","volume":"1702","author":"TR Zijp","year":"2023","unstructured":"Zijp TR, van Hateren K, Kuiper H, Jongedijk EM, Touw DJ. Ultra-high throughput dual channel liquid chromatography with tandem mass spectrometry for quantification of four immunosuppressants in whole-blood for therapeutic drug monitoring. J Chromatogr A. 2023;1702:464086.","journal-title":"J Chromatogr A"},{"key":"969_CR20","doi-asserted-by":"crossref","unstructured":"Siniscalchi A, Pierucci E, Faenza S. Anaesthetic and perioperative management for liver transplantation. In: Abdominal solid organ transplantation. Cham: Springer International Publishing; 2015. pp. 143\u201368.","DOI":"10.1007\/978-3-319-16997-2_9"},{"issue":"1","key":"969_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/bcp.12174","volume":"77","author":"MH Abdel Jalil","year":"2014","unstructured":"Abdel Jalil MH, Hawwa AF, McKiernan PJ, Shields MD, McElnay JC. Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. Br J Clin Pharmacol. 2014;77(1):130\u201340.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"969_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/FTD.0b013e31829dcbcd","volume":"36","author":"FT Musuamba","year":"2014","unstructured":"Musuamba FT, Guy-Viterbo V, Reding R, Verbeeck RK, Wallemacq P. Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. Ther Drug Monit. 2014;36(1):54\u201361.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"969_CR23","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00228-013-1501-0","volume":"69","author":"V Guy-Viterbo","year":"2013","unstructured":"Guy-Viterbo V, Scohy A, Verbeeck RK, Reding R, Wallemacq P, Musuamba FT. Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. Eur J Clin Pharmacol. 2013;69(8):1533\u201342.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"969_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.clpt.2006.06.008","volume":"80","author":"M Fukudo","year":"2006","unstructured":"Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther. 2006;80(4):331\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"969_CR25","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/archdischild-2013-305888","volume":"100","author":"P Lancia","year":"2015","unstructured":"Lancia P, Jacqz-Aigrain E, Zhao W. Choosing the right dose of tacrolimus. Arch Dis Child. 2015;100(4):406\u201313.","journal-title":"Arch Dis Child"},{"key":"969_CR26","doi-asserted-by":"crossref","unstructured":"Riva N, Schaiquevich P, C\u00e1ceres Guido P, Halac E, Dip M, Imventarza O. Pharmacoepidemiology of tacrolimus in pediatric liver transplantation. Pediatr Transplant. 2017;21(5).","DOI":"10.1111\/petr.12982"},{"issue":"1","key":"969_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00228-012-1296-4","volume":"69","author":"N Han","year":"2013","unstructured":"Han N, Yun H, Hong J, Kim IW, Ji E, Hong SH, et al. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. 2013;69(1):53\u201363.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5\u20136","key":"969_CR28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00228-005-0933-6","volume":"61","author":"M Antignac","year":"2005","unstructured":"Antignac M, Hulot JS, Boleslawski E, Hannoun L, Touitou Y, Farinotti R, et al. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol. 2005;61(5\u20136):409\u201316.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"969_CR29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2165\/11318080-000000000-00000","volume":"48","author":"K Benkali","year":"2009","unstructured":"Benkali K, Pr\u00e9maud A, Picard N, R\u00e9rolle JP, Toupance O, Hoizey G, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet. 2009;48(12):805\u201316.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"969_CR30","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1592\/phco.26.8.1069","volume":"26","author":"JY Lee","year":"2006","unstructured":"Lee JY, Hahn HJ, Son IJ, Suh KS, Yi NJ, Oh JM, et al. Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. Pharmacotherapy. 2006;26(8):1069\u201377.","journal-title":"Pharmacotherapy"},{"key":"969_CR31","first-page":"9","volume":"2","author":"B Prusinskas","year":"2021","unstructured":"Prusinskas B, Ohlsson S, Kathemann S, Pilic D, Kampmann K, B\u00fcscher R, et al. Role of tacrolimus C\/D ratio in the first year after pediatric liver transplantation. Front Pediatr. 2021;2:9.","journal-title":"Front Pediatr"},{"issue":"7","key":"969_CR32","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/S0041-1345(00)01413-5","volume":"32","author":"RH Hu","year":"2000","unstructured":"Hu RH, Lee PH, Tsai MK. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. Transplant Proc. 2000;32(7):1689\u201392.","journal-title":"Transplant Proc"},{"issue":"8","key":"969_CR33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/sj.bmt.1703224","volume":"28","author":"P Jacobson","year":"2001","unstructured":"Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage R. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant. 2001;28(8):753\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"969_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2710.2007.00850.x","volume":"32","author":"D Li","year":"2007","unstructured":"Li D, Lu W, Zhu JY, Gao J, Lou YQ, Zhang GL. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther. 2007;32(5):505\u201315.","journal-title":"J Clin Pharm Ther"},{"issue":"6\u20137","key":"969_CR35","first-page":"479","volume":"57","author":"S Fukatsu","year":"2001","unstructured":"Fukatsu S, Yano I, Igarashi T, Hashida T, Takayanagi K, Saito H, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57(6\u20137):479\u201384.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"969_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00007890-199107000-00015","volume":"52","author":"K Abu-Elmagd","year":"1991","unstructured":"Abu-Elmagd K, Fung JJ, Alessiani M, Jain A, Venkataramanan R, Warty VS, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation. 1991;52(1):71\u20137.","journal-title":"Transplantation"},{"issue":"1","key":"969_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/FPC.0b013e32834e1641","volume":"22","author":"KA Birdwell","year":"2012","unstructured":"Birdwell KA, Grady B, Choi L, Xu H, Bian A, Denny JC, et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet Genom. 2012;22(1):32\u201342.","journal-title":"Pharmacogenet Genom"},{"issue":"3","key":"969_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2133\/dmpk.DMPK-13-RG-095","volume":"29","author":"D Chen","year":"2014","unstructured":"Chen D, Guo F, Shi J, Zhang C, Wang Z, Fan J, et al. Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients. Drug Metab Pharmacokinet. 2014;29(3):249\u201353.","journal-title":"Drug Metab Pharmacokinet"},{"key":"969_CR39","first-page":"37","volume":"14","author":"P Marquet","year":"2024","unstructured":"Marquet P, Anglicheau D, Humeau A, Adrouche S, Saada L, Bisiaux J, et al. Tacrolimus dose requirement in de novo adult kidney transplant patients treated with Adoport\u00ae can be anticipated. Transpl Int. 2024;14:37.","journal-title":"Transpl Int"},{"issue":"6","key":"969_CR40","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1177\/10781552211029046","volume":"28","author":"TM Gu","year":"2022","unstructured":"Gu TM, Lewis JS, Le H, Bubalo JS. Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations. J Oncol Pharm Pract. 2022;28(6):1357\u201362.","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"969_CR41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/1078155214539825","volume":"21","author":"GD Peksa","year":"2015","unstructured":"Peksa GD, Schultz K, Fung HC. Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2015;21(6):409\u201315.","journal-title":"J Oncol Pharm Pract"},{"issue":"8","key":"969_CR42","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1097\/00007890-199604270-00026","volume":"61","author":"CL Osowski","year":"1996","unstructured":"Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation. 1996;61(8):1268\u201372.","journal-title":"Transplantation"},{"issue":"10","key":"969_CR43","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1111\/cts.13571","volume":"16","author":"A Alghamdi","year":"2023","unstructured":"Alghamdi A, Seay S, Hooper DK, Varnell CD, Darland L, Mizuno T, et al. Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients. Clin Transl Sci. 2023;16(10):1768\u201378.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"969_CR44","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1046\/j.1397-3142.2003.00103.x","volume":"7","author":"CB Mahnke","year":"2003","unstructured":"Mahnke CB, Sutton RM, Venkataramanan R, Michaels M, Kurland G, Boyle GJ, et al. Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation. Pediatr Transplant. 2003;7(6):474\u20138.","journal-title":"Pediatr Transplant"},{"key":"969_CR45","doi-asserted-by":"crossref","unstructured":"Kitazawa F, Fuchida S ichi, Kado Y, Ueda K, Kokufu T, Okano A, et al. Pharmacokinetic interaction between tacrolimus and fentanyl in patients receiving allogeneic hematopoietic stem cell transplantation. Ann Transplant. 2017;22:575\u201380.","DOI":"10.12659\/AOT.904505"},{"issue":"7","key":"969_CR46","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1345\/aph.1K628","volume":"42","author":"S Lam","year":"2008","unstructured":"Lam S, Partovi N, Ting LS, Ensom MH. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother. 2008;42(7):1037\u201347.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"969_CR47","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40262-012-0007-8","volume":"51","author":"TK Bergmann","year":"2012","unstructured":"Bergmann TK, Barraclough KA, Lee KJ, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Clin Pharmacokinet. 2012;51(11):711\u201341.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"969_CR48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1472-8206.2008.00644.x","volume":"23","author":"S Park","year":"2009","unstructured":"Park S, Felipe CR, Pinheiro-Machado PG, Garcia R, Fernandes FB, Casarini DE, et al. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus. Fundam Clin Pharmacol. 2009;23(1):137\u201345.","journal-title":"Fundam Clin Pharmacol"},{"issue":"4","key":"969_CR49","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0041-1345(98)00234-6","volume":"30","author":"NA Undre","year":"1998","unstructured":"Undre NA, Sch\u00e4fer A. Factors affecting the pharmacokinetics of Tacrolimus in the first year after Renal transplantation. Transpl Proc. 1998;30(4):1261\u20133.","journal-title":"Transpl Proc"},{"issue":"10","key":"969_CR50","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1432-2277.2003.tb00230.x","volume":"16","author":"EM van Duijnhoven","year":"2003","unstructured":"van Duijnhoven EM, Boots JMM, Christiaans MHL, Stolk LML, Undre NA, van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int. 2003;16(10):721\u20135.","journal-title":"Transpl Int"},{"issue":"11","key":"969_CR51","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","volume":"41","author":"U Christians","year":"2002","unstructured":"Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with Tacrolimus. Clin Pharmacokinet. 2002;41(11):813\u201351.","journal-title":"Clin Pharmacokinet"},{"issue":"1\u20132","key":"969_CR52","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3109\/03602539709037591","volume":"29","author":"S Rendic","year":"1997","unstructured":"Rendic S, Di CFJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29(1\u20132):413\u2013580.","journal-title":"Drug Metab Rev"},{"issue":"10","key":"969_CR53","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00002018-200225100-00003","volume":"25","author":"T van Gelder","year":"2002","unstructured":"van Gelder T. Drug interactions with Tacrolimus. Drug Saf. 2002;25(10):707\u201312.","journal-title":"Drug Saf"},{"issue":"4","key":"969_CR54","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1067\/mcp.2000.110215","volume":"68","author":"J McCune","year":"2000","unstructured":"McCune J. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther. 2000;68(4):356\u201366.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"969_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40780-023-00310-0","volume":"9","author":"Y Ohno","year":"2023","unstructured":"Ohno Y, Oriyama T, Honda A, Kurokawa M, Takada T. Induction of CYP3A activity by dexamethasone may not be strong, even at high doses: insights from a case of tacrolimus co-administration. J Pharm Health Care Sci. 2023;9(1):39.","journal-title":"J Pharm Health Care Sci"},{"issue":"5","key":"969_CR56","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/bcpt.13780","volume":"131","author":"DB Iversen","year":"2022","unstructured":"Iversen DB, Andersen NE, Dalg\u00e5rd Dunvald A, Potteg\u00e5rd A, Stage TB. Drug metabolism and drug transport of the 100 most prescribed oral drugs. Basic Clin Pharmacol Toxicol. 2022;131(5):311\u201324.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"969_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-02968-z","author":"H Veenhof","year":"2020","unstructured":"Veenhof H, Schouw HM, Besouw MTP, Touw DJ, Gracchi V. Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study. Eur J Clin Pharmacol. 2020. https:\/\/doi.org\/10.1007\/s00228-020-02968-z.","journal-title":"Eur J Clin Pharmacol"},{"key":"969_CR58","doi-asserted-by":"publisher","unstructured":"Elmeliegy M, Vourvahis M, Guo C, Wang DD. Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies. Clin Pharmacokinet [Internet]. 123AD [cited 2024 May 13];59:699\u2013714. https:\/\/doi.org\/10.1007\/s40262-020-00867-1.","DOI":"10.1007\/s40262-020-00867-1"},{"key":"969_CR59","doi-asserted-by":"crossref","unstructured":"Huwyler J, Wright M, Gutmann H, Drewe J. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr Drug Metab [Internet]. 2006 [cited 2024 May 13];7(2):119\u201326. https:\/\/pubmed.ncbi.nlm.nih.gov\/16472102\/.","DOI":"10.2174\/138920006775541534"},{"issue":"12","key":"969_CR60","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00228-020-02968-z","volume":"76","author":"H Veenhof","year":"2020","unstructured":"Veenhof H, Schouw HM, Besouw MTP, Touw DJ, Gracchi V. Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study. Eur J Clin Pharmacol. 2020;76(12):1667\u201373.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"969_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1753-5174.2010.00032.x","volume":"4","author":"MS Park","year":"2011","unstructured":"Park MS, Okochi H, Benet LZ. Is Ciprofloxacin a Substrate of P-glycoprotein? Arch Drug Inf. 2011;4(1):1\u20139.","journal-title":"Arch Drug Inf"},{"issue":"8","key":"969_CR62","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1177\/0091270007303765","volume":"47","author":"R Borrows","year":"2007","unstructured":"Borrows R, Chusney G, Loucaidou M, James A, Goel S, Borrows S, et al. Analysis of factors influencing tacrolimus levels and immunoassay bias in renal transplantation. J Clin Pharmacol. 2007;47(8):1035\u201342.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"969_CR63","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2165\/00003088-200645020-00003","volume":"45","author":"S Federico","year":"2006","unstructured":"Federico S, Carrano R, Capone D, Gentile A, Palmiero G, Basile V. Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2006;45(2):169\u201375.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"969_CR64","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1124\/dmd.113.055400","volume":"42","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Wang F, Li Q, Zhu M, Du A, Tang W, et al. Amlodipine metabolism in human liver microsomes and roles of CYP3A4\/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014;42(2):245\u20139.","journal-title":"Drug Metab Dispos"},{"key":"969_CR65","unstructured":"Leroy S, Fargue S, Bensman A, Desch\u00eanes G, Jacqz-Aigrain E, Ulinski T. Tacrolimus adverse events in transplant recipients with diarrhoea or calcium channel blockers: systematic review. Med Case Stud [Internet]. 2011;2(7):58\u201368. http:\/\/www.academicjournals.org\/MCS."},{"issue":"4","key":"969_CR66","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s13318-013-0168-3","volume":"39","author":"N Vavic","year":"2014","unstructured":"Vavic N, Rancic N, Dragojevic-Simic V, Draskovic-Pavlovic B, Bokonjic D, Ignjatovic L, et al. The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study. Eur J Drug Metab Pharmacokinet. 2014;39(4):243\u201353.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"969_CR67","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1124\/jpet.104.068908","volume":"311","author":"ET Williams","year":"2004","unstructured":"Williams ET, Leyk M, Wrighton SA, Davies PJA, Loose DS, Shipley GL, et al. Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther. 2004;311(2):728\u201335.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"969_CR68","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2008.202","volume":"84","author":"M Kennedy","year":"2008","unstructured":"Kennedy M. Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence. Clin Pharmacol Ther. 2008;84(6):662\u201373.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"969_CR69","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1177\/0091270008323754","volume":"48","author":"DJ Greenblatt","year":"2008","unstructured":"Greenblatt DJ, von Moltke LL. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol. 2008;48(11):1350\u20135.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"969_CR70","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1210\/jcem-73-2-428","volume":"73","author":"SR Rose","year":"1991","unstructured":"Rose SR, Municchi G, Barnes KM, Kamp GA, Uriarte MM, Ross JL, et al. Spontaneous growth hormone secretion increases during puberty in normal girls and boys*. J Clin Endocrinol Metab. 1991;73(2):428\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"969_CR71","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1021\/acs.molpharmaceut.0c00574","volume":"18","author":"Y Mai","year":"2021","unstructured":"Mai Y, Dou L, Yao Z, Madla CM, Gavins FKH, Taherali F, et al. Quantification of P-glycoprotein in the gastrointestinal tract of humans and rodents: methodology, gut region, sex, and species matter. Mol Pharm. 2021;18(5):1895\u2013904.","journal-title":"Mol Pharm"},{"issue":"6","key":"969_CR72","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","volume":"59","author":"M Elmeliegy","year":"2020","unstructured":"Elmeliegy M, Vourvahis M, Guo C, Wang DD. Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies. Clin Pharmacokinet. 2020;59(6):699\u2013714.","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00969-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00969-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00969-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:03:03Z","timestamp":1771866183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00969-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00969-w","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This research did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors. Competing interests: Femke A. Elzinga, Andrea R. Hernandez-Hernandez, Hubert P.J. van der Doef, Jos G.W. Kosterink, Erik A.H. Loeffen, Ren\u00e9 Scheenstra, Arno R. Bourgonje, Daan J. Touw, and Paola Mian declare that they have no financial or nonfinancial interests that are directly or indirectly related to the work submitted for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Data can be accessed upon reasonable request through the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"This is a retrospective and descriptive study. The Medical Ethics Review Board of the University Medical Center Groningen (METc UMCG) has confirmed that this study does not fall under the scope of the Medical Research Involving Human Subjects Act (WMO), and therefore, WMO approval is not required (METc 2023\/191).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Due to the retrospective and descriptive nature of this study, the need for informed consent was waived by the UMCG METc (METc 2023\/191).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"No identifiable personal data is included in this study; therefore, consent for publication was not required.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Femke A. Elzinga and Andrea R. Hernandez-Hernandez contributed equally tot his work. They were responsible for the data extraction, data analysis, and writing the initial draft of the manuscript. Paola Mian, Daan J. Touw, Hubert P.J. van der Doef, and Arno R. Bourgonje contributed to the conceptualization of the study, data analysis, and writing and reviewing the manuscript. Jos G.W. Kosterink, Erik A.H. Loeffen, and Ren\u00e9 Scheenstra contributed to reviewing the manuscript. All authors approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}